{{Rsnum
|rsid=1801279
|Gene=NAT2
|Chromosome=8
|position=18400194
|Orientation=plus
|ReferenceAllele=G
|MissenseAllele=A
|GMAF=0.02204
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=NAT2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 2.7 | 97.3
| HCB | 0.0 | 0.7 | 99.3
| JPT | 0.0 | 0.9 | 99.1
| YRI | 0.0 | 22.1 | 77.9
| ASW | 0.0 | 12.7 | 87.3
| CHB | 0.0 | 0.7 | 99.3
| CHD | 0.0 | 0.9 | 99.1
| GIH | 0.0 | 1.0 | 99.0
| LWK | 0.0 | 16.4 | 83.6
| MEX | 0.0 | 3.6 | 96.4
| MKK | 0.0 | 7.7 | 92.3
| TSI | 0.0 | 1.0 | 99.0
| HapMapRevision=28
}}

[[rs1801279]] is a SNP in the [[NAT2]] gene, potentially encoding a variant detoxifying protein known as an N-acetyltransferase, but which [[NAT2]] variant depends on which other [[NAT2]] SNPs were also inherited. See the discussion of the [[NAT2]] gene for a more complete explanation.

The risk allele for this SNP is [[rs1801279]](A).

{{ neighbor
| rsid = 1041983
| distance = 91
}}

{{PharmGKB
|RSID=rs1801279
|Name_s=NAT2:ARG64GLN; NAT2:191G>A; NAT2:M4; Included in NAT2*14 alleles(A-G).
|Gene_s=NAT2
|Feature=
|Evidence=PubMed ID:10667461; PubMed ID:10971207; PubMed ID:17434923; PubMed ID:7668286; PubMed ID:7920692; PubMed ID:8102597; PubMed ID:9156695; Web Resource:http://louisville.edu/medschool/pharmacology/Human.NAT2.pdf
|Annotation=Homozygous A allele is slow acetylator phenotype (altered rates of metabolism of arylamines). May be associated with higher risk for bladder cancer and lower risk for colorectal cancer.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145093
}}

{{PMID Auto
|PMID=22092036
|Title=Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes
|OA=1
}}

{{PMID Auto
|PMID=16112301
|Title=NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
|OA=1
}}

{{PMID Auto
|PMID=16416399
|Title=Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes.
|OA=1
}}

{{PMID Auto
|PMID=18268115
|Title=Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk.
|OA=1
}}

{{PMID Auto
|PMID=18547414
|Title=Genotyping panel for assessing response to cancer chemotherapy.
|OA=1
}}

{{PMID Auto
|PMID=18664443
|Title=Unraveling ambiguous NAT2 genotyping data.
}}

{{PMID Auto
|PMID=18680467
|Title=Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.
|OA=1
}}

{{PMID Auto
|PMID=18773084
|Title=Multiple advantageous amino acid variants in the NAT2 gene in human populations.
|OA=1
}}

{{PMID Auto
|PMID=18936436
|Title=Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994.
|OA=1
}}

{{PMID Auto
|PMID=20043821
|Title=Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data.
|OA=1
}}

{{GET Evidence
|gene=NAT2
|aa_change=Arg64Gln
|aa_change_short=R64Q
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1801279
|overall_frequency_n=301
|overall_frequency_d=10758
|overall_frequency=0.0279792
|n_genomes=10
|n_genomes_annotated=0
|n_haplomes=10
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|nblosum100=0
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}